Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

ImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'

* ImmunoForge's LMT15 Platform combines high BBB permeability with proprietary long-acting ELP technology * Technology excellence validated by winning first place at 'Novo Nordisk Partnering Day Korea 2026' SEOUL, South Korea, April 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical...

2026-04-22 14:13 2439

Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA

BEIJING, April 22, 2026 /PRNewswire/ -- Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results...

2026-04-22 11:09 2598

NOVI Health's Hybrid Care Model Closes Gap Between Clinical Trials and Real-World GLP-1 Outcomes

An estimated ~14.7% weight loss at 18 months was achieved in one of the first studies evaluating integrated GLP-1 therapies and digital coaching in a multi-ethnic Asian population (n=708). This matched gold-standard clinical trial results, with digital coaching acting as a measurable multiplier. ...

2026-04-22 11:00 3745

Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain

— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker reductions — — Preliminary data from 180 mg cohort shows trends of clinical stabilization (ALSFRS-R) — — Phase II trial is now actively dosing participants — CHICAGO, April 2...

2026-04-22 10:10 3567

Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi

TOKYO, April 22, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D projects for the development of drugs for malaria and neglected tropical diseases (NTDs).2 Investment of a...

2026-04-22 10:00 3181

Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting

CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, includi...

2026-04-22 08:59 4122

Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, April 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2026-04-22 08:00 3432

Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine

SHANGHAI, April 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment ...

2026-04-22 08:00 4402

ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026

Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting SEOUL, South Korea, April 21, 2026 /PRNewswire/ -- ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that resu...

2026-04-22 07:30 2785

Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery

CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry's first Longevity Board (Board). The initiative provides scienti...

2026-04-21 21:05 4679

HKeybio Launches World's First NHP Hidradenitis Suppurativa Model with High Clinical Consistency to Tackle Global Drug R&D Bottleneck

BOSTON and SUZHOU, China, April 21, 2026 /PRNewswire/ -- HKeybio Tech., a global leader in non-human primate (NHP) experimental animal model research and development, today announced the official launch of theworld's first NHP Hidradenitis Suppurativa (HS) model, based on over ten years of resear...

2026-04-21 20:30 3229

Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)

* Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) * Findings emphasize clinical decision-making in long-term management of inflammatory bo...

2026-04-21 20:00 4371

Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026

HONG KONG, April 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatme...

2026-04-21 10:54 3354

Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile

– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23% – No Grade 3 or higher adverse events related to RZ-001 observed – Highlights clinical potential of RNA trans-splicing ribozyme platform technology SEOUL, South...

2026-04-21 10:10 3002

Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time

SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Adminis...

2026-04-21 10:00 4315

AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL

SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data we...

2026-04-20 22:00 3813

Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows

* The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure * The standalone booth features STAgora simulation and an interactive touchscreen experience * An enhanced CURECA model is presented, illustrating next-generation automated labora...

2026-04-20 21:00 3287

Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region

* With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner * Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions ...

2026-04-20 19:30 2550

Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026

SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myelom...

2026-04-20 18:45 3168

Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline

SAN DIEGO, April 20, 2026 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce itsparticipation in the AACR Annual Meeting 2026, taking place April 19–22, 2026 in San Diego, California. At the meeting, the ...

2026-04-20 16:17 3120

1 ... 3 4 567 8 9 ... 342

Week's Top Stories

Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia

[Picked up by 286 media titles]

2026-05-15 17:00

Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia

Peach Blossoms Celebrates Three Massive Wins - Black Pearl Restaurant Guide 2026, Asia's 50 Best Restaurants 2026 Extended List and Tatler Best 20 Restaurants in Singapore 2026

[Picked up by 285 media titles]

2026-05-12 14:00